CiMaas moves it’s clinical production site to InSciTe in Sittard-Geleen. Working together in the Biomedical Accelerator Matrix, CiMaas and InSciTe are joining forces to bring a cure for cancer one step closer to reality.
MAASTRICHT, Mercurius Beleggingsmaatschappij B.V. and Werker Beleggingsmaatschappij B.V. invest in CiMaas B.V. to realize cancer immunotherapy. CiMaas is now able to start a clinical trial in late 2017 for lung cancer patients with a cellular vaccine that will stimulate the patients’ own immune system to fight the disease.
The province of Limburg, through LBDF, has awarded CiMaas a subsidy for further development of the new technology for large scale production of NK cell immunotherapy. Under the subsidy, CiMaas collaborates with the department of Haematology of the MUMC+ and an American biotech company to further optimize the treatment.
CiMaas has signed an agreement with London-based Cancer Research Technology, the commercial arm of the charity Cancer Research UK, and the University of Copenhagen under which CiMaas will test a proprietary monoclonal antibody in combination with natural killer cells for the treatment of cancer.
As of 18 february 2016 CiMaas has appointed the renowned oncologists Professor Dr Joachim Aerts and Professor Dr John Haanen as member of the Scientific Advisory Board of CiMaas.
CiMaas focuses on the development of cellular immunotherapy for the treatment of cancer. One of these therapies is based on healthy donor derived Natural Killer cells to treat cancer patients.
CiMaas BV, a company developing cellular immunotherapy for cancer, and PharmaCell BV, a leading Contract Manufacturing Organization for Cellular Therapies and Regenerative Medicine in Europe, have agreed to collaborate in the clinical development of CiMaas’ products.
Dr Yvo Graus, PhD, MBA, will join the management team of CiMaas. Yvo Graus is an immunologist and has extensive experience in biotechnology. Through his activities at Genmab, Yvo gained great experience in product development from bench to bedside. He worked on the development of products in the laboratory to making them applicable in patients…. Read more »
Drs D.A. van den Noort, MD, and member of the Board of Directors of Bioseutica, has been appointed as first member of the Supervisory Board of CiMaas. Mister van den Noort has tremendous experience in the pharmaceutical industry and is well acquainted with investment instruments in Biotech start-ups. Daan van den Noort: “CiMaas is an… Read more »
Out of 75 applicants, 20 young companies have been nominated to receive an innovation award in November 2015. CiMaas is one of these 20 companies that is in the running for 1 of the 5 awards to be given by the Province of Limburg. For further information on the Innovaward see: innovaward.nl Specifically for CiMaas:… Read more »